State Street’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

State Street’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,243,571	Closed	-$133M	–	4771
2023 Q1	$133M	Sell	1,243,571 -104,609	-8%	-$12M	0.01%	1006
2022 Q4	$148M	Sell	1,348,180 -237,894	-15%	-$15.4M	0.01%	921
2022 Q3	$93.6M	Buy	1,586,074 +1,100,857	+227%	+$50.4M	0.01%	1143
2022 Q2	$13.7M	Sell	485,217 -502,243	-51%	-$14.6M	﹤0.01%	2503
2022 Q1	$37.3M	Buy	987,460 +546,100	+124%	+$21.6M	﹤0.01%	1937
2021 Q4	$17.5M	Buy	441,360 +244,094	+124%	+$7.64M	﹤0.01%	2569
2021 Q3	$4.68M	Buy	197,266 +41,465	+27%	+$979K	﹤0.01%	3272
2021 Q2	$3.83M	Buy	+155,801	New	+$3.48M	﹤0.01%	3360

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

State Street's RXDX Position: Q2 2023 in Review

State Street sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,243,571 shares — an estimated $133M sold.

State Street first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $148M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

State Street reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 1,243,571 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $133M.
State Street first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
State Street's Prometheus Biosciences, Inc. Common Stock position peaked at $148M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.